Drug intelligence / Profile preview

3-(1-(4-bromophenyl)-5-phenyl-1H-pyrazol-3-yl)pyridine

Development stage: Preclinical
Modality: Small Molecules

Overview

COMPOUND 5D, chemically known as 3-(1-(4-bromophenyl)-5-phenyl-1H-pyrazol-3-yl)pyridine, is a synthetic pyrazole derivative. It has demonstrated significant cytotoxicity against mammary carcinoma cells. Its mechanism of action involves binding to the ligand binding domain of estrogen receptor alpha (ER-α) and reducing ER-α expression in tumor cells, thereby acting as an ER-α antagonist. This antagonistic effect contributes to its potent inhibitory activity against mammary carcinoma cells.

Targets

ESR1 (ERα)

Beyond the preview

Go deeper on 3-(1-(4-bromophenyl)-5-phenyl-1H-pyrazol-3-yl)pyridine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-(1-(4-bromophenyl)-5-phenyl-1H-pyrazol-3-yl)pyridine.

Explore the full profile